First Horizon (FHN) Buy Rating Reiterated at Raymond James; With $24.0 Target; Vascular Biogenics Ltd. (VBLT) Had 5 Bullish Analysts

December 6, 2017 - By Vivian Park

Among 18 analysts covering First Horizon National Corporation (NYSE:FHN), 9 have Buy rating, 0 Sell and 9 Hold. Therefore 50% are positive. First Horizon National Corporation has $23.0 highest and $13 lowest target. $20.08’s average target is -0.67% below currents $20.215 stock price. First Horizon National Corporation had 46 analyst reports since July 21, 2015 according to SRatingsIntel. The stock of First Horizon National Corporation (NYSE:FHN) has “Neutral” rating given on Thursday, December 15 by Bank of America. Keefe Bruyette & Woods maintained First Horizon National Corporation (NYSE:FHN) rating on Tuesday, November 28. Keefe Bruyette & Woods has “Buy” rating and $22.0 target. Deutsche Bank maintained it with “Hold” rating and $15.50 target in Monday, September 26 report. On Wednesday, June 14 the stock rating was maintained by Jefferies with “Buy”. The firm earned “Equalweight” rating on Monday, July 18 by Barclays Capital. The rating was initiated by Guggenheim on Thursday, October 8 with “Buy”. Raymond James upgraded First Horizon National Corporation (NYSE:FHN) on Thursday, August 10 to “Outperform” rating. The firm has “Strong Buy” rating by Raymond James given on Wednesday, November 8. Hovde Group upgraded the stock to “Outperform” rating in Tuesday, January 5 report. RBC Capital Markets maintained the shares of FHN in report on Monday, October 19 with “Sector Perform” rating.

Among 5 analysts covering Vascular Biogenics (NASDAQ:VBLT), 5 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Vascular Biogenics had 13 analyst reports since August 24, 2015 according to SRatingsIntel. The company was maintained on Tuesday, November 7 by H.C. Wainwright. The firm has “Buy” rating given on Tuesday, June 28 by H.C. Wainwright. As per Wednesday, March 9, the company rating was maintained by JMP Securities. As per Monday, November 9, the company rating was initiated by Piper Jaffray. Chardan Capital Markets maintained Vascular Biogenics Ltd. (NASDAQ:VBLT) on Friday, October 23 with “Buy” rating. H.C. Wainwright maintained Vascular Biogenics Ltd. (NASDAQ:VBLT) rating on Tuesday, October 3. H.C. Wainwright has “Buy” rating and $11.0 target. The rating was maintained by Roth Capital on Monday, September 28 with “Buy”. The rating was maintained by H.C. Wainwright with “Buy” on Tuesday, August 15. The firm has “Buy” rating given on Monday, August 24 by Roth Capital. On Monday, September 21 the stock rating was upgraded by JMP Securities to “Mkt Outperform”. See Vascular Biogenics Ltd. (NASDAQ:VBLT) latest ratings:

07/11/2017 Broker: H.C. Wainwright Rating: Buy New Target: $11.0 Maintain
30/10/2017 Broker: Chardan Capital Markets Rating: Buy New Target: $20.0
03/10/2017 Broker: H.C. Wainwright Rating: Buy New Target: $11.0 Maintain
15/08/2017 Broker: H.C. Wainwright Rating: Buy New Target: $11.0000 Maintain

The stock increased 1.56% or $0.1 during the last trading session, reaching $6.5. About 59,880 shares traded. Vascular Biogenics Ltd. (NASDAQ:VBLT) has risen 78.91% since December 6, 2016 and is uptrending. It has outperformed by 62.21% the S&P500.

Vascular Biogenics Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for cancer. The company has market cap of $193.21 million. The companyÂ’s program is based on its proprietary vascular targeting system platform technology, which utilizes genetically targeted therapy to destroy newly formed or angiogenic blood vessels. It currently has negative earnings. The Company’s lead product candidate is VB-111, a gene biologic that is in Phase III clinical trials for the treatment of recurrent glioblastoma, an aggressive form of brain cancer; and has completed Phase II clinical trials for recurrent platinum-resistant ovarian cancer, as well as for iodine-resistant differentiated thyroid cancer.

Analysts await First Horizon National Corporation (NYSE:FHN) to report earnings on January, 12. They expect $0.28 EPS, up 21.74% or $0.05 from last year’s $0.23 per share. FHN’s profit will be $65.58 million for 18.05 P/E if the $0.28 EPS becomes a reality. After $0.32 actual EPS reported by First Horizon National Corporation for the previous quarter, Wall Street now forecasts -12.50% negative EPS growth.

First Horizon National Corporation operates as the bank holding firm for First Tennessee Bank National Association that provides various financial services in the United States and internationally. The company has market cap of $4.74 billion. The firm offers general banking services for consumers, businesses, financial institutions, and governments. It has a 17.89 P/E ratio. It also provides investment, financial planning, trust, asset management, and cash management services.

The stock increased 1.43% or $0.285 during the last trading session, reaching $20.215. About 1.40M shares traded. First Horizon National Corporation (NYSE:FHN) has risen 21.88% since December 6, 2016 and is uptrending. It has outperformed by 5.18% the S&P500.

Investors sentiment decreased to 1.04 in 2017 Q2. Its down 0.31, from 1.35 in 2017Q1. It dived, as 26 investors sold First Horizon National Corporation shares while 85 reduced holdings. 29 funds opened positions while 86 raised stakes. 197.17 million shares or 0.78% more from 195.63 million shares in 2017Q1 were reported. Royal National Bank & Trust Of Canada holds 0.01% or 1.50 million shares in its portfolio. Frontier Ltd Liability Corp owns 4.63 million shares for 0.59% of their portfolio. Parametric Portfolio Assocs Ltd Liability Co stated it has 675,328 shares. Gemmer Asset Mngmt Ltd has 0% invested in First Horizon National Corporation (NYSE:FHN). Great Lakes Advisors Ltd Llc has invested 0.06% of its portfolio in First Horizon National Corporation (NYSE:FHN). Jarislowsky Fraser holds 0.01% or 88,097 shares in its portfolio. Rafferty Asset Ltd Limited Liability Company holds 0.02% or 34,294 shares in its portfolio. Glenmede Trust Na owns 403 shares for 0% of their portfolio. Ubs Asset Management Americas holds 0% or 191,480 shares in its portfolio. Axa holds 0% in First Horizon National Corporation (NYSE:FHN) or 38,100 shares. Public Employees Retirement Systems Of Ohio stated it has 85,225 shares or 0.01% of all its holdings. Us Commercial Bank De owns 16,216 shares or 0% of their US portfolio. Ing Groep Nv reported 48,440 shares stake. Goldman Sachs Grp accumulated 4.86 million shares or 0.02% of the stock. Channing stated it has 354,937 shares or 0.24% of all its holdings.

Since June 15, 2017, it had 0 buys, and 1 sale for $91,995 activity. On Thursday, June 15 the insider PALMER VICKI R sold $91,995.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter: